Cancer Clinical Trials Results

Cancer Answer Line: 866.223.8100

Cancer Answer Line:

866.223.8100

Cancer Clinical Trials Results

IRBCCTitleHospitalStagePhaseDisease
07-267 Collection of Blood and Tissue from Patients with Upper Aerodigestive Malignancies for Research Purposes (The UAM Tissue Resource)Main Campus  Esophageal, Head & Neck, Lung, Mesothelioma, Thyroid
2559 Genetic and molecular analysis of tumors of the Nervous system and their coveringsMain Campus  Brain
3952 Analysis of Human Bone Marrow from Donors Undergoing a Bone Marrow HarvestMain Campus  Aplastic Anemia, Bone Cancer, Bone Marrow Failure, Leukemia, Acute Lymphoblastic (ALL) , Leukemia, Acute Myeloid (AML), Leukemia, Chronic Lymphocytic (CLL), Leukemia, Chronic Myeloid (CML), Lymphoma, Lymphoma, Hodgkin, Lymphoma, Non - Hodgkin, Multiple Myeloma, Myelodysplastic Syndrome (MDS)
4639 Tissue and Body Fluid Analysis from Renal Cell Cancer PatientsMain Campus  Renal
5024 Collection of Blood & Bone Marrow from Normal Volunteers & Patients for Research Purposes (No Funding)Main Campus  Bone Marrow Failure
7538 Collection of Blood and Bone Marrow Samples of Hematologic Diseases for Research PurposesMain Campus  Multiple Myeloma
A03120114-332Phase III Trial fo Enzalutamide versus Enzalutamide, Abiraterone and Prednisone for castration resistant metastatic prostate cancerBeachwood, Fairview, Florida Weston, Hillcrest, Independence, Main Campus, North Coast Cancer, Strongsville, Wooster Phase 3Prostate
A04120214-353A RANDOMIZED PHASE III STUDY OF BENDAMUSTINE PLUS RITUXIMAB VERSUS IBRUTINIB PLUS RITUXIMAB VERSUS IBRUTINIB ALONE IN UNTREATED OLDER PATIENTS (≥ 65 YEARS OF AGE) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)Beachwood, Fairview, Hillcrest, Independence, Main Campus, North Coast Cancer, Parma, Strongsville, Wooster Phase 3Leukemia, Chronic Lymphocytic (CLL)
ABTC 120213-927Phase I Study of MK-1775 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients with Recurrent GlioblastomaMain Campus Phase 1Brain, Glioblastoma
ACLN 181213-173A Phase 2 Randomized Study of Dalantercept in CombinationMain Campus  Renal
ALEX 1Z1111-245Paroxysmal Hemoglobinuria RegistryMain Campus  PNH
AMGN 1911CC 00164A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects with Acute Leukemias and Related DisordersMain Campus Phase 1Leukemia, Acute Lymphoblastic (ALL) , Leukemia, Acute Myeloid (AML)
ARRY 16231113-1209The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum (ARRAY BioPharma Inc.)Fairview, Hillcrest, Main Campus  Gynecologic
ARRY 1A1314-258A Multicenter, Randomized, Open-label, Phase 2 Study of Carfilzomib With or Without ARRY-520 in Patients With Advanced Multiple MyelomaMain Campus Phase 2Multiple Myeloma
ASTX 151212-974A Study of HSP90 Inhibitor AT13387 Alone and in Combination with Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)Main Campus  Lung
BAX 1Z1414-475Phase 3b Continuation Study of the Safety and Efficacy of Prophylactic BAX 855 in PTPs with Severe Hemophilia AMain Campus Phase 3Hemophilia A
BAY 151212-1139Phase Ib / II study of BAY 1000394 in combination with cisplatin / etoposide or carboplatin/etoposide as first-line therapy in subjects with extensive disease small cell lung cancerMain Campus Phase 1, Phase 2Lung
BMTCTN 120214-419Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCTMain Campus  Blood & Marrow Transplant (BMT)
BMTCTN 120514-326A Randomized, Multi-Center, Phase III Study of Allogeneic Stem Cell Transplantation Comparing Regimen Intensity in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia and A Multi-Center, Phase III, Randomized Trial of Reduced Intensity Conditioning (RIC) and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies Main Campus Phase 3Blood & Marrow Transplant (BMT), Hematologic Malignancy
BNIT 181111-1163A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate CancerMain Campus Phase 3Prostate
123456789

Cancer Answers & Appointments

Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.

Monday through Friday from 8 a.m. – 4:30 p.m. (ET).

Referrals

Resources for medical professionals

  • Outpatient appointment referrals: 216.444.7923 or 866.223.8100
  • Inpatient hospital transfers: 800.553.5056
  • Referring Physician Concierge: 216.444.6196 or 216.312.4910.

Clinical Trials

Search available cancer clinical trials by disease, hospital, phase or number.

This information is provided by Cleveland Clinic and is not intended to replace the medical advice of your doctor or health care provider. Please consult your health care provider for advice about a specific medical condition.

© Copyright 2014 Cleveland Clinic. All rights reserved.

Cleveland Clinic Mobile Site